Free Trial
NYSE:NVO

Novo Nordisk A/S (NVO) Stock Price, News & Analysis

Novo Nordisk A/S logo
$102.77 -2.50 (-2.37%)
(As of 11/21/2024 ET)

About Novo Nordisk A/S Stock (NYSE:NVO)

Key Stats

Today's Range
$101.51
$103.22
50-Day Range
$99.82
$137.00
52-Week Range
$94.73
$148.15
Volume
5.36 million shs
Average Volume
4.50 million shs
Market Capitalization
$461.18 billion
P/E Ratio
33.26
Dividend Yield
0.70%
Price Target
$144.50
Consensus Rating
Moderate Buy

Company Overview

Novo Nordisk A/S is a global healthcare company specializing in the research, development, production, and marketing of pharmaceutical products to treat diabetes, obesity, and other chronic diseases. The company was founded in 1923 in Denmark and is headquartered in Bagsværd, Denmark.

Novo Nordisk has operations in more than 80 countries, including production facilities in nine countries, and employs approximately 48,500 people worldwide.

Novo Nordisk's mission is to discover and develop innovative medicines to help people with chronic diseases lead longer, healthier lives. The company's key therapeutic areas include diabetes, obesity, hemophilia, growth hormone therapy, and other severe chronic diseases. Novo Nordisk is the world's largest producer of insulin and has been at the forefront of diabetes care for more than 95 years.

Lars Fruergaard Jørgensen is the President and CEO of Novo Nordisk A/S, a position he has held since 2017. Jørgensen joined Novo Nordisk in 1991 and has held various management positions, including Executive Vice President and Head of Corporate Development, Strategy and Biopharmaceuticals.

Novo Nordisk has consistently delivered strong financial performance over the past few years. Novo Nordisk's profit margin has remained consistently high, with a net margin of approximately 30%. In terms of debt, Novo Nordisk has maintained a conservative approach. Novo Nordisk's debt has kept pace with its assets for several years. The company's cash reserves have not always been healthy, but in 2022 Novo Nordisk made a profit for the first time since 2018.

Novo Nordisk's valuation metrics compare favorably to industry peers. It has a price-to-earnings ratio in line with its peers but a price-to-book ratio significantly higher than the industry average. Novo Nordisk's high P/B ratio reflects its strong brand, market position, and financial performance.

Novo Nordisk's stock has performed well over the past few years, with a 3-year annualized return of around 23%. The stock price has shown some volatility, with significant price movements in response to regulatory and market news related to diabetes and obesity markets. 

Novo Nordisk operates in the highly competitive and rapidly evolving pharmaceutical industry, specifically in diabetes and obesity markets. The global diabetes market is expected to grow at a CAGR of 5.7% from 2022 to 2027, driven by the increasing prevalence of diabetes, especially in emerging markets, and the growing demand for innovative diabetes treatments. In the obesity market, the global prevalence of obesity has been steadily increasing, and it is expected to continue to rise, driving demand for effective obesity treatments.

Novo Nordisk faces intense competition from several large and small pharmaceutical companies in the diabetes and obesity markets. The company's main competitors in the diabetes market include Sanofi, Eli Lilly, and AstraZeneca, while its main competitors in the obesity market include Roche, Novartis, and Eisai.

The company's competitive position is based on factors such as the quality and effectiveness of its products, its research and development capabilities, its brand reputation, and ability to adapt to changing market dynamics.

Novo Nordisk is also subject to various regulatory and political issues that can impact its operations and financial performance. The company must comply with strict regulatory requirements in each country it operates, including the US FDA and the European Medicines Agency. Changes in regulatory requirements, such as changes to reimbursement policies, can significantly impact the company's financial performance.

Novo Nordisk has several growth opportunities to pursue in the coming years. The company is investing heavily in research and development to develop new and innovative treatments for diabetes and obesity, as well as other chronic diseases. Novo Nordisk has a strong pipeline of potential products in development, including GLP-1 receptor agonists, which have shown promise in clinical trials for treating obesity.

The company also expands in emerging markets, such as China and India, with significant and growing demand for diabetes and obesity treatments. Novo Nordisk has established partnerships with local companies in these markets to help drive growth and increase product access.

Novo Nordisk has pursued acquisitions and partnerships to expand its product offerings and capabilities. In 2021, the company acquired Prothena's ATTR amyloidosis program, a potential treatment for a rare and debilitating disease. This acquisition will strengthen Novo Nordisk's position in the rare disease market.

Novo Nordisk faces several risks and challenges that could impact its operations and financial performance. The company's success is heavily dependent on the success of its products in the diabetes and obesity markets, and any setbacks in clinical trials or product launches could significantly impact its financial performance.

In addition, Novo Nordisk faces regulatory and political risks, as changes in regulations or policies could impact its ability to operate or sell its products in specific markets. The company is also subject to intellectual property risks, as competitors may seek to challenge its patents and market their products.

Novo Nordisk also faces risks related to supply chain disruptions and production delays, as well as cybersecurity and data privacy risks.

Novo Nordisk A/S Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
85th Percentile Overall Score

NVO MarketRank™: 

Novo Nordisk A/S scored higher than 85% of companies evaluated by MarketBeat, and ranked 168th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Novo Nordisk A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Novo Nordisk A/S has only been the subject of 2 research reports in the past 90 days.

  • Read more about Novo Nordisk A/S's stock forecast and price target.
  • Earnings Growth

    Earnings for Novo Nordisk A/S are expected to grow by 25.16% in the coming year, from $3.22 to $4.03 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Novo Nordisk A/S is 33.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.63.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Novo Nordisk A/S is 33.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 101.15.

  • Price to Earnings Growth Ratio

    Novo Nordisk A/S has a PEG Ratio of 1.32. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Novo Nordisk A/S has a P/B Ratio of 25.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Novo Nordisk A/S's valuation and earnings.
  • Percentage of Shares Shorted

    0.13% of the outstanding shares of Novo Nordisk A/S have been sold short.
  • Short Interest Ratio / Days to Cover

    Novo Nordisk A/S has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Novo Nordisk A/S has recently decreased by 4.87%, indicating that investor sentiment is improving.
  • Dividend Yield

    Novo Nordisk A/S has a dividend yield of 0.71%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Novo Nordisk A/S does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Novo Nordisk A/S is 23.30%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 17.87% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.

  • Read more about Novo Nordisk A/S's dividend.
  • Percentage of Shares Shorted

    0.13% of the outstanding shares of Novo Nordisk A/S have been sold short.
  • Short Interest Ratio / Days to Cover

    Novo Nordisk A/S has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Novo Nordisk A/S has recently decreased by 4.87%, indicating that investor sentiment is improving.
  • News Sentiment

    Novo Nordisk A/S has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 34 news articles for Novo Nordisk A/S this week, compared to 27 articles on an average week.
  • Search Interest

    98 people have searched for NVO on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.
  • MarketBeat Follows

    Only 46 people have added Novo Nordisk A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of -16% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.07% of the stock of Novo Nordisk A/S is held by insiders.

  • Percentage Held by Institutions

    Only 11.54% of the stock of Novo Nordisk A/S is held by institutions.

  • Read more about Novo Nordisk A/S's insider trading history.
Receive NVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.

NVO Stock News Headlines

Minsk, Belarus - January 3, 2019: Prepaid payment card Payoneer and money in background — Stock Editorial Photography
3 Top Stocks Crushing Q3 Earnings With Strong 2024 Guidance (NVO)
Hims & Hers, Payoneer, and Astera Labs lead Q3 earnings with standout revenue growth, forecast upgrades, and strategic wins—stocks to watch for growth potential
Altimmune weight loss
How Altimmune Could Grab a Big Chunk of the GLP-1 Market (NVO)
Altimmune is working on a developmental weight loss drug that could have strong benefits for an important segment of GLP-1 users.
Download Our Tesla Ebook For Free
Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.
Viking Therapeutics weight loss pills
Viking Therapeutics Stock: A Pre-Election Bet Worth Considering (NVO)
Viking Therapeutics is making headway in the weight loss drug market; but even though the payoff is years away, there's still plenty of upside for investors
Photo of cans of energetic monster — Stock Editorial Photography
Monster and Celsius Energized: Which Stock Offers More Upside? (NVO)
Energy drinks face negative publicity and competition, leading to sell-offs in Monster and Celsius. Increasing foot traffic may offer hope for a recovery.
Novo Nordisk AS ADR
Is Novo Nordisk Stock a Buy Right Now?
Novo Nordisk launches obesity drug Wegovy in China
See More Headlines

NVO Stock Analysis - Frequently Asked Questions

Novo Nordisk A/S's stock was trading at $103.45 on January 1st, 2024. Since then, NVO stock has decreased by 0.7% and is now trading at $102.77.
View the best growth stocks for 2024 here
.

Novo Nordisk A/S (NYSE:NVO) posted its quarterly earnings results on Thursday, August, 10th. The company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.34 by $0.02. The company earned $7.93 billion during the quarter, compared to analysts' expectations of $8.44 billion. Novo Nordisk A/S had a trailing twelve-month return on equity of 86.32% and a net margin of 35.03%.

Novo Nordisk A/S's stock split before market open on Wednesday, September 20th 2023. The 2-1 split was announced on Wednesday, September 20th 2023. The newly issued shares were distributed to shareholders after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Novo Nordisk A/S subsidiaries include Dicerna Pharmaceuticals, Emisphere Technologies, Corvidia Therapeutics, Ziylo, Calibrium, MB2 LLC, Xellia Pharmaceuticals, and others.

Novo Nordisk A/S's top institutional investors include Jennison Associates LLC (0.45%), FMR LLC (0.40%), Fisher Asset Management LLC (0.30%) and Loomis Sayles & Co. L P (0.19%).
View institutional ownership trends
.

Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Novo Nordisk A/S investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), ServiceNow (NOW), Advanced Micro Devices (AMD), Salesforce (CRM) and Eli Lilly and Company (LLY).

Company Calendar

Last Earnings
8/10/2023
Ex-Dividend for 8/26 Dividend
8/16/2024
Dividend Payable
8/26/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
1/29/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Employees
63,370
Year Founded
1923

Price Target and Rating

Average Stock Price Target
$144.50
High Stock Price Target
$160.00
Low Stock Price Target
$115.00
Potential Upside/Downside
+40.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$12.15 billion
Pretax Margin
44.13%

Debt

Sales & Book Value

Annual Sales
$33.71 billion
Cash Flow
$3.02 per share
Book Value
$3.96 per share

Miscellaneous

Outstanding Shares
4,487,530,000
Free Float
4,484,391,000
Market Cap
$461.95 billion
Optionable
Optionable
Beta
0.42

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NYSE:NVO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners